Skip to main content
. Author manuscript; available in PMC: 2010 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2009 Jul 7;8(7):2057–2066. doi: 10.1158/1535-7163.MCT-09-0256

Figure 4. Cytotoxicity assays of compounds predicted with the TLDA expression repository.

Figure 4

(G) Cytotoxicity assays for ABCB1-overexpressing HEK293 (●) and parental HEK293 (○) cells with NSC693871. (A-B) Cytotoxicity assays for ABCB1-overexpressing HEK293 (●) and parental HEK293 (○) cells with NSC634791 and Bouvardin, respectively. (C) Cytotoxicity assays for ABCC1-overexpressing HEK293 (●) and parental HEK293 (○) cells with Saframycin. (D-E-F) Cytotoxicity assays for ABCG2-R482 (WT) overexpressing HEK293 (●) and parental HEK293 (○) cells with Bikaverin, Sparoxomycin A1 and NSC265473, respectively. CCK-8 reagent was used for cytotoxicity assays as described in Materials and Methods. Dose response curves were derived from three independent experiments. In all panels, error bars indicate standard deviation.